Research Centre

Clinical Research is expanding at Marsden Eye Specialists. Dr Jennifer Arnold and Dr Ashish Agar co-ordinates the research team of Ophthalmologists, Orthoptists and Registered Nurses. The department currently has 10 ongoing international and local clinical trials. The main focus of research is on new treatments for Age Related Macular Degeneration, Diabetic Macular Oedema, Retinal Vein Occlusions and Glaucoma. Patients enrolled in these trials have access to new advanced treatments that are in the final stages of development prior to approval and release.

Please contact Clinical Trials Co-ordinator Trish Forsyth on or email [javascript protected email address] if you would like further information.

Research Team

Dr Jennifer Arnold – Principal Investigator (AMD, DME, BRVO, CRVO Trials)

Dr Ashish Agar – Principal Investigator (Glaucoma Trials)

Dr Terence Tan, Dr Helene Cass, Dr Gavin Stringfellow, Dr Alan Luckie – Sub Investigators.

Ivy Chow, Angela Chung, Lara Grieg, Vivian Ghebrial, Mitchell Bagley – VA, OCT, FA technicians

Trish Forsyth – Study Co-ordinator

Anh Nguyen – Clinical Trials Assistant

Julie Boland – Study Nurse

Current recruiting Clinical Trials

Wet AMD

  • Chengdu Kanghong Biotechnology Co., Ltd - KHB-1801- Phase 3, A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Agerelated Macular Degeneration.(PANDA)
  • Roche Products Pty Limited (Roche) GR40844 - Phase 3, Multi-Center, randomized, double-masked, active comparatorcontrolled study to evaluate RO6867461 in patients with neovascular age-related macular degeneration (LUCERNE) (Commencing soon)

Dry AMD

  • Apellis – A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS) (Commencing soon)
  • ISIS 696844-CS5 - Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (IONIS) (Commencing soon)

Diabetes - DME

  • Novartis Pharmaceuticals Australia Pty Limited - Kestrel A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)
  • Opthea Limited - OPT-302-1003 - Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema (OPTHEA)
  • Roche Products Pty Limited (Roche) - GR40398 - Phase 3, multicenter, randomized, double-masked, active comparatorcontrolled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (RHINE)

RVO

  • Bayer AG - BAY86-5321/17514 -A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (Centera)
  • Novartis Research and Development - CRTH258C2302 An Eighteen-Month, Two-Arm, Randomized, Double- Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion
    (RAVEN) (Commencing soon)

Glaucoma

  • Allergan 1924-701-007 - A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45. Glaucoma Treatment System in Patients with Angle Closure Glaucoma (XPLORE).(Commencing soon) Development Phase: Pivotal